Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
出版年份 2019 全文链接
标题
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
作者
关键词
-
出版物
Gastroenterology Report
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-10-26
DOI
10.1093/gastro/goz061
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials
- (2019) E Fontana et al. ANNALS OF ONCOLOGY
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
- (2019) C Luchini et al. ANNALS OF ONCOLOGY
- INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS
- (2019) Nicolas J Llosa et al. CLINICAL CANCER RESEARCH
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
- (2019) Aparna Raj Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
- (2019) Eric Xueyu Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
- (2019) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
- (2019) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
- (2019) Dan Aderka et al. LANCET ONCOLOGY
- Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis
- (2019) Lianzhou Yang et al. OncoTargets and Therapy
- The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells
- (2019) P. M. Gershovich et al. BIOCHEMISTRY-MOSCOW
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
- (2019) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
- (2019) Andrew Georgiadis et al. CLINICAL CANCER RESEARCH
- Inherited DNA-Repair Defects in Colorectal Cancer
- (2018) Saud H. AlDubayan et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing
- (2018) Marie Lorans et al. Clinical Colorectal Cancer
- The Impact of Microsatellite stability status in colorectal cancer
- (2018) Ruby Gupta et al. CURRENT PROBLEMS IN CANCER
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- DNA mismatch repair in cancer
- (2018) Marina Baretti et al. PHARMACOLOGY & THERAPEUTICS
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
- (2018) Sean P. Pitroda et al. Nature Communications
- Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
- (2018) Muhammad Zubair Afzal et al. Journal for ImmunoTherapy of Cancer
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
- (2018) Alexander Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer
- (2018) M Chalabi et al. ANNALS OF ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients
- (2018) Marc Van den Eynde et al. CANCER CELL
- Evolution of Metastases in Space and Time under Immune Selection
- (2018) Mihaela Angelova et al. CELL
- Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
- (2018) Harry H. Yoon et al. CLINICAL CANCER RESEARCH
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The prognostic value of immunoscore in patients with colorectal cancer: A systematic review and meta-analysis
- (2018) Guorui Sun et al. Cancer Medicine
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation
- (2017) Jun Gong et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
- (2017) Dirk Zboralski et al. Cancer Immunology Research
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
- (2017) Rachel Pearlman et al. JAMA Oncology
- Emerging Opportunities and Challenges in Cancer Immunotherapy
- (2016) T. L. Whiteside et al. CLINICAL CANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Global patterns and trends in colorectal cancer incidence and mortality
- (2016) Melina Arnold et al. GUT
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
- (2016) Pedro N Aguiar et al. Immunotherapy
- A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.
- (2016) Austin G. Duffy et al. JOURNAL OF CLINICAL ONCOLOGY
- Landscape of tumor-infiltrating T cell repertoire of human cancers
- (2016) Bo Li et al. NATURE GENETICS
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
- (2015) J Carrasco et al. BRITISH JOURNAL OF CANCER
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983
- (2015) Erik Tanis et al. EUROPEAN JOURNAL OF CANCER
- Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy
- (2015) G. Xue et al. JNCI-Journal of the National Cancer Institute
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
- (2015) Mihaela Angelova et al. GENOME BIOLOGY
- Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy
- (2015) G. Xue et al. JNCI-Journal of the National Cancer Institute
- Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
- (2015) N. van Baren et al. Cancer Immunology Research
- Human CD4+CD39+regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+exosomes or CD73+cells
- (2014) P. J. Schuler et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy
- (2012) L. van de Laar et al. BLOOD
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
- (2012) Tracy L. McGaha et al. IMMUNOLOGICAL REVIEWS
- Radiation Therapy to Convert the Tumor Into an In Situ Vaccine
- (2012) Silvia C. Formenti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
- (2011) L Ferdinande et al. BRITISH JOURNAL OF CANCER
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Interleukin-15 biology and its therapeutic implications in cancer
- (2011) Jason C. Steel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutator phenotypes due to DNA replication infidelity
- (2010) Mercedes E. Arana et al. SEMINARS IN CANCER BIOLOGY
- Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
- (2008) M. Dechant et al. CANCER RESEARCH
- Immunogenic cancer cell death: a key-lock paradigm
- (2008) Antoine Tesniere et al. CURRENT OPINION IN IMMUNOLOGY
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- How tumours escape mass destruction
- (2008) T J Stewart et al. ONCOGENE
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started